Alfasigma to acquire fellow Italian drugmaker Sofar

Italian drugmaker Alfasigma has signed an agreement to acquire the entire share capital of Sofar, a company with over half a century of operational history in the research, production and marketing of drugs, medical devices and food supplements.

Financial terms of the transaction, which is expected to complete in October, have not been disclosed.

With this acquisition, the Alfasigma group adds to its portfolio the products of Sofar, which closed 2021 with a turnover of over 113 million euros ($114 million), double-digit growth compared to the previous year. The company, with over 54 years of history, 150 references marketed in more than 10 therapeutic areas and over 300 employees, owns an advanced research laboratory located in Bergamo and a production plant in Trezzano Rosa (Milan).